Siddha interventions for children with Autism

An open clinical trial for the management of Maantha sanni(Autism spectrum disorder)with polyherbal drug Sagalanoi chooranam along with varmam - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106413

Enrollment

Registered

2026-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: Sagalanoi chooranam: Adult dose is 1500mg.The pediatric dosage is calculated by using youngs rule. For 3-6 years :300-500mg 7-12 years: 600-750mg The drug will be administered twice a

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed as Autism spectrum disorder with ISAA score 70-200

Exclusion criteria

Exclusion criteria: Autism with cerebral palsy,Autism with seizures,Autism with hearing loss or visual impairments,Autism with congenital anomalies,Autism child receiving psychotropic medications,ADHD

Design outcomes

Primary

Measure	Time frame
Reduction in overall autism symptom severity with MCID value greater than or equal to 10 pointsTimepoint: 18 months	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr M Meenakshi sundaram

National Institute of siddha

mmssiddha@rediffmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026